Trial reportDrug safety2004
Safety of telmisartan in patients with arterial hypertension : an open-label observational study.
Trial report in Drug safety, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02338232 (Pilot Study of Telmisartan), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation
Who cites it
15 citing papers in PubMed, 57 citations in OpenAlex.
- Progress in Synthesis and Pharmacology of Telmisartan.Chemistry & biodiversity · 2026Review
- Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients.Frontiers in pharmacology · 2023Article
- Phytochemical Composition, Antioxidant Activity, α-Glucosidase and Acetylcholinesterase Inhibitory Activity of Quinoa Extract and Its Fractions.Molecules (Basel, Switzerland) · 2022Article
- Telmisartan is effective to ameliorate metabolic syndrome in rat model - a preclinical report.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Article
- Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms.International journal of clinical practice · 2017Article
- Genetic polymorphism of ACE and the angiotensin II type1 receptor genes in children with chronic kidney disease.Journal of inflammation (London, England) · 2011Article
- Review
- New standards in hypertension and cardiovascular risk management: focus on telmisartan.Vascular health and risk management · 2010Review
- Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care.Vascular health and risk management · 2010Article
- Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?Vascular health and risk management · 2007Review
- Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects.PPAR research · 2007Article
- High prevalence of ACE DD genotype among north Indian end stage renal disease patients.BMC nephrology · 2006Article
- Metabolic effects of telmisartan in spontaneously hypertensive rats.Naunyn-Schmiedeberg's archives of pharmacology · 2006Article
- Review
- Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.Cardiovascular diabetology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether age, gender, concomitant disease and/or previous or present antihypertensive medication affect the safety or antihypertensive efficacy of telmisartan in the treatment of arterial hypertension. STUDY DESIGN AND
methodsIn this large-scale, open-label postmarketing surveillance study, German physicians systematically documented their observations concerning patients with essential hypertension on case report forms. Patients were treated for 6 months with telmisartan (40-80 mg once daily). Data were analysed using direct group comparisons and multiple linear regression analysis.
resultsA total of 19 870 patients (52.3% males, mean age 59.1 years) were evaluated, of whom 47.6, 18.3, 13.2 and 2.1%, respectively, had concomitant hypercholesterolaemia, diabetes mellitus, congestive heart failure and renal insufficiency. In the overall group, adverse events were reported in 1.9% of patients. Global tolerability was rated as very good, good, moderate or poor, respectively, in 74.7, 22.1, 0.7 and 0.5% of patients; tolerability was similar across all subgroups of patients. Telmisartan treatment did not increase serum creatinine or potassium in any subgroup, including >400 patients with impaired renal function (basal creatinine 1.73 mg/dL). Telmisartan had no adverse effects on glucose, triglyceride or cholesterol levels. In the overall group, telmisartan reduced mean +/- SD systolic blood pressure from 171.3 +/- 16.4 mm Hg to 141.3 +/- 12.0 mm Hg and diastolic blood pressure from 99.0 +/- 9.4 mm Hg to 83.4 +/- 6.9 mm Hg. Reductions were very similar between genders, age groups and patients with and without comorbidities, and not dependent on prior or concomitant treatment with other antihypertensive drugs.
conclusionThe safety and efficacy of telmisartan found in controlled studies is maintained in a large postmarketing population that included sizeable patient subgroups potentially at higher risk for adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.